Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IgG4 subclass in malignant melanoma

M Daveau, J Pavie-Fischer, L Rivat

    Journal of the National Cancer Institute
    |February 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

    Nature medicine·2022
    Same author

    Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

    Nature medicine·2022
    Same author

    Nrf2-dependent persistent oxidative stress results in stress-induced vulnerability to depression.

    Molecular psychiatry·2016
    Same author

    Nrf2-dependent persistent oxidative stress results in stress-induced vulnerability to depression.

    Molecular psychiatry·2016
    Same author

    Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin.

    Molecular psychiatry·2007
    Same author

    [Low doses ketamine: antihyperalgesic drug, non-analgesic].

    Annales francaises d'anesthesie et de reanimation·2005
    Same journal

    Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates.

    Journal of the National Cancer Institute·2026
    Same journal

    Breast cancer risk prediction with artificial intelligence: promise, calibration, and clinical readiness.

    Journal of the National Cancer Institute·2026
    Same journal

    RE：Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.

    Journal of the National Cancer Institute·2026
    Same journal

    Worsening frailty and declining quality of life in older survivors of non-metastatic breast cancer.

    Journal of the National Cancer Institute·2026
    Same journal

    Longitudinal effects of comorbidities on brain structure and cognition in older breast cancer survivors.

    Journal of the National Cancer Institute·2026
    Same journal

    Response to Wang et al. and Shen et al.

    Journal of the National Cancer Institute·2026
    See all related articles

    Immunoglobulin G4 (IgG4) levels in melanoma patients often change with disease progression. Abnormal IgG4 levels were more common in advanced melanoma stages, suggesting a link to disease dissemination.

    Area of Science:

    • Immunology
    • Oncology
    • Medical Research

    Background:

    • Melanoma is a significant form of skin cancer.
    • Immunoglobulin G4 (IgG4) is a specific antibody subclass with incompletely understood roles in disease.

    Purpose of the Study:

    • To investigate the relationship between IgG4 subclass levels and the stage of melanoma.
    • To determine if IgG4 alterations correlate with melanoma dissemination.

    Main Methods:

    • Analysis of 397 serum samples from 185 melanoma patients.
    • Classification of sera based on melanoma disease stage (I, II, and III).
    • Quantification and comparison of IgG4 levels across different disease stages.

    Main Results:

    • Abnormal IgG4 levels (increased or decreased) were observed in melanoma patients.

    Related Experiment Videos

  • Higher frequencies of IgG4 abnormalities were found in Stage II (55%) and Stage III (53%) melanoma compared to Stage I (19%).
  • Elevated IgG4 titers were predominantly detected in advanced stages of the disease.

    • Conclusions:

    • Alterations in IgG4 subclass levels are associated with melanoma progression and dissemination.
    • The precise biological role of increased IgG4 in melanoma requires further investigation.
    • Increased IgG4 may potentially be linked to the development of facilitating antibodies in melanoma.